# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Satchel Paige (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML047-SYN-TD
- Date: 1979-07-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Delphine Whitaker-Osei, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review on the day of the pulmonology consultation. **S**

## History of present illness

Mr. Paige returns two weeks after intake and was seen this morning by Dr. Lindqvist-Bello of pulmonology, who did spirometry before and after albuterol, an arterial blood gas and a six-minute walk. He uses his albuterol once or twice a day, mostly before walking to the store, with the spacer. He is still breathless after one flight of stairs or a block on the level and coughs up a little clear sputum each morning. He has had no flare-ups in the past year. He takes atorvastatin each evening without muscle aches. He asked to see his breathing numbers and how they were worked out, and said he had read that lung tests used to be scored differently for Black patients; Dr. Lindqvist-Bello went through the results with him. **S**

| Element | Detail |
|---|---|
| Spirometry | Post-bronchodilator FEV1 2.02 L, FVC 3.48 L, FEV1/FVC 0.58; FEV1 61% predicted (GLI Global) |
| Blood gas | pH 7.42, PaCO2 40, PaO2 70 mm Hg on room air |
| Six-minute walk | 360 m; lowest saturation 90 percent |
| Symptoms | CAT 18; mMRC 2 |
| Exacerbations | None in the past year |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Breathless after a block; morning cough with a little clear sputum; no wheeze at rest or hemoptysis |
| Cardiovascular | Negative | No chest pain, palpitations, orthopnea or ankle swelling |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |

3 systems reviewed. **S**

## Current medications

- Albuterol 90 micrograms per inhalation metered-dose inhaler with a spacer, two inhalations every four hours as needed for breathlessness **S**
- Umeclidinium 62.5 micrograms with vilanterol 25 micrograms dry powder inhaler (a LAMA with a LABA), one inhalation once a day **S**
- Atorvastatin 20 mg tablet once a day **S**

## Allergies

- No known allergy **S**

## Objective

BP 132/80 mmHg; pulse 82 bpm; respirations 18/min; temperature 36.6 °C; oxygen saturation 94% on room air; weight 82.4 kg; BMI 22.6 kg/m². All vital signs are synthetic.

FEV1 before bronchodilator: 1.92 L (low); FEV1 after bronchodilator: 2.02 L (low); FVC after bronchodilator: 3.48 L; FEV1/FVC after bronchodilator: 0.58 (low); FEV1 percent predicted after bronchodilator (GLI Global): 61% (low); Arterial pH: 7.42 [pH]; PaCO2: 40 mmHg; PaO2 (room air): 70 mmHg (low); Six-minute walk distance: 360 m (low). All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Tall and lean; talks in full sentences; blood pressure 132/80, pulse 82, oxygen saturation 94 percent on room air |
| Respiratory | Barrel-shaped chest; reduced breath sounds throughout; prolonged expiration; no wheeze or crackles |
| Cardiovascular | Regular rhythm; heart sounds soft; no edema |
| Inhaler technique | Albuterol with spacer correct; dry powder inhaler technique taught with a placebo device, with a strong, deep breath in, and repeated back correctly |

All examination findings are synthetic. **S**

## Assessment and plan

1. **COPD, GOLD grade 2, group B** (J44.9). Dr. Lindqvist-Bello confirms COPD: a post-bronchodilator FEV1/FVC of 0.58, below 0.70 and below the lower limit of normal. With the race-neutral GLI Global equations his FEV1 is 61% of predicted, GOLD grade 2; race-specific equations for Black men would have predicted a lower normal value and put him at about 70%, understating his impairment. A CAT of 18 and mMRC of 2 with no exacerbation in the past year place him in GOLD group B, for which a LAMA with a LABA is the first maintenance treatment. With eosinophils of 0.08 x 10^3/uL and no exacerbations, an inhaled corticosteroid would add risk without benefit. His PaO2 of 70 mm Hg and lowest walking saturation of 90 percent mean he needs no long-term or ambulatory oxygen. **S**
   - Umeclidinium 62.5 micrograms with vilanterol 25 micrograms, one inhalation each morning.
   - Albuterol as needed.
   - Pulmonary rehabilitation twice a week for about ten weeks.
   - Low-dose CT for lung cancer screening after shared decision-making.
   - A COPD action plan, spoken and written.
2. **Hyperlipidemia on atorvastatin** (E78.5). Two weeks on atorvastatin without muscle symptoms. **S**
   - Lipid panel at the eight-week visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Spirometry: post-bronchodilator FEV1/FVC and FEV1 % predicted (race-neutral GLI Global) | At diagnosis, then at least yearly or with a clear change | Completed today | FEV1 1.92 L before and 2.02 L after albuterol; FVC 3.48 L; FEV1/FVC 0.58; FEV1 61% predicted by GLI Global: obstruction, GOLD grade 2 |
| Examination | Pulse oximetry at rest | Every visit | Completed today | 94 percent on room air, read with the knowledge that oximetry can overestimate saturation in darker skin |
| Laboratory | Arterial blood gas | When saturation is 92 percent or less, for oxygen assessment, or when oximetry may be unreliable | Completed today | Done because his oximetry may overstate his oxygen level: pH 7.42, PaCO2 40, PaO2 70 mm Hg |
| Survey | Symptoms: CAT and mMRC dyspnea scale | Every visit | Completed today | CAT 18; mMRC 2 (no LOINC survey code; recorded in the note) |
| Survey | Exacerbations in the past 12 months (moderate and severe) and GOLD group | Every visit | Completed today | None in the past year; GOLD group B |
| Self-management | Smoking status and cessation support | Every visit | Completed today | Former smoker, about 30 pack-years, stopped eleven years ago |
| Examination | BMI and nutrition | Every visit | Completed today | BMI 22.6; weight steady |
| Laboratory | Blood eosinophil count | At baseline and when an inhaled corticosteroid is considered | Up to date | 0.08 x 10^3/uL at intake: argues against an inhaled corticosteroid |
| Laboratory | Alpha-1 antitrypsin | Once, at diagnosis | Up to date | 142 mg/dL at intake, normal |
| Medication safety | Inhaler technique, adherence and side effects (dry mouth, urinary retention) | Every visit | Completed today | Spacer technique correct; dry powder inhaler taught today with a placebo device |
| Examination | ECG and cardiovascular risk | At baseline; reassess after exacerbations | Up to date | ECG normal and NT-proBNP 92 pg/mL at intake |
| Self-management | Vaccines: influenza, pneumococcal, RSV, COVID-19, Tdap, zoster | Yearly review | Completed today | PCV20 and Tdap at intake; influenza, RSV and COVID-19 due in the autumn; zoster to be given then |
| Imaging | Low-dose CT lung cancer screening | Yearly at 50 to 80 with 20 or more pack-years, while within fifteen years of quitting | Ordered | Eligible (73, about 30 pack-years, stopped eleven years ago); chose screening after shared decision-making; booked in one week |
| Referral | Pulmonary rehabilitation | Offer when mMRC is 2 or more, or CAT 10 or more; within three weeks of a hospital discharge for an exacerbation | Referred | mMRC 2 and CAT 18; program twice a week from the second week of August; a church volunteer will drive him |
| Examination | Six-minute walk test | At rehabilitation entry and exit, and for oxygen assessment | Completed today | 360 m on room air; lowest saturation 90 percent |
| Examination | Long-term oxygen assessment | When resting PaO2 is 55 mm Hg or less (60 with cor pulmonale or polycythemia) or saturation 88 percent or less, confirmed twice | Not indicated | PaO2 70 mm Hg at rest and lowest walking saturation 90 percent: no long-term or ambulatory oxygen (moderate desaturation, LOTT) |
| Self-management | Written and spoken COPD action plan | At diagnosis, reviewed after each exacerbation | Completed today | Explained aloud and given in writing: daily inhaler, when to use the reliever, call the clinic the same day for more breathlessness or a change in sputum, call 911 for breathlessness at rest, chest pain or confusion |
| Medication safety | Statin safety: muscle symptoms | Every visit | Completed today | No muscle aches |
| Referral | Pulmonology consultation | At diagnosis | Completed today | Seen by Dr. Lindqvist-Bello today |

## Goal progress

- Find the cause of the breathlessness. Outcome by 1979-07-28: COPD confirmed by spirometry (post-bronchodilator FEV1/FVC 0.58); heart failure unlikely (NT-proBNP 92, normal ECG); alpha-1 antitrypsin normal. **S**
- Walk farther with less breathlessness. In progress; target 1979-10-27. **S**
- Fewer and milder flare-ups, treated early. In progress; target 1980-07-14. **S**
- LDL below 100 mg/dL. In progress; target 1979-09-08. **S**
- Vaccines up to date. In progress; target 1979-10-06. **S**

## Medication changes

- Started: Umeclidinium 62.5 micrograms with vilanterol 25 micrograms dry powder inhaler (a LAMA with a LABA), one inhalation once a day **S**

## Guideline basis

- Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025), Global Initiative for Chronic Obstructive Lung Disease
- Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement (2023), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine 2023;207(8):978-995)
- CMID: Clinical Monitoring Intelligence Database, COPD and hyperlipidemia monographs (2026), Aether Forge
- Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine 2023;208(4):e7-e26)
- Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine 2020;202(10):e121-e141)
- A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation (LOTT) (2016), Long-Term Oxygen Treatment Trial Research Group (New England Journal of Medicine 2016;375(17):1617-1627)
- Racial Bias in Pulse Oximetry Measurement (2020), Sjoding MW, et al. (New England Journal of Medicine 2020;383(25):2477-2478)
- Lung Cancer: Screening (2021), U.S. Preventive Services Task Force
- Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Start the new inhaler tomorrow morning. Low-dose CT in one week. Rehabilitation from the second week of August. Eight-week review with a lipid panel. **S**
- Next scheduled visit 1979-09-08: eight-week review: symptoms on the new inhaler, technique, rehabilitation, the screening CT and the lipid response. **S**
